Women in Ophthalmology summer symposium

Article

Ophthalmic Women Leaders (OWL) and Women In Ophthalmology, Inc. (WIO) are pleased to announce their joint partnership in presenting the WIO Summer Symposium.

BODEGA BAY, CA and MILWAUKEE, WI‐ July 01, 2010‐ Ophthalmic Women Leaders (OWL) and Women In Ophthalmology, Inc. (WIO) are pleased to announce their joint partnership in presenting the WIO Summer Symposium. The programme will be held from August 12‐15 at the Pinehurst Resort in Pinehurst, NC, and will be packed with great educational sessions as well as opportunities to relax and network with attendees.

This annual event boasts an educational component in addition to opportunities for networking among attendees, which consistently tops 150 women. The Symposium provides solid scientific and practice management information to clinicians, researchers, and other professionals who are engaged in the diagnosis and treatment of eye disease. This year's program also promises to feature an increased focus on education from a variety of professionals within the medical and ophthalmic worlds.

“Past attendees have formed great relationships, bonds and dialogues with other attendees, especially since the relationship between the industry and physicians is evolving,”states Eydie Miller‐Ellis, Summer Symposium Program Chair and Professor of Clinical Ophthalmology at the Scheie Eye Institute. “The Summer Symposium allows us to collaborate, grow and innovate as women in this ophthalmic industry. As a combined unit with OWL, we have career and life experiences that we can all benefit from. Adding the mixture of clinical and industry, we will all come out of the meeting more empowered than we were before.”

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.